Correlation between oculometric measures and clinical assessment in ALS patients participating in a phase IIb clinical drug trial

Objective: Oculometric measures (OM) can be extracted from eye movements during presentation of visual stimuli. Studies have indicated the benefit of OM in assessment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS). We used a new software-based platform for the extraction of OM during patients’ assessment. Our objective was to examine the correlation between OM and clinical assessment as a part of a clinical drug trial. Methods: 32 ALS patients (mean age 60.75 ± 10.36 years, 13 females), were assessed using a validated score (ALSFRS-R), and a novel software-based oculometric platform (NeuraLight, Israel) as a part of a clinical drug trial. Correlations of ALSFRS-R with OM were calculated and compared with matched healthy subjects’ data (N = 129). Results: A moderate correlation was found between ALSFRS-R and corrective saccadic latency (R = 0.52, p = 0.002). Fixation time during smooth pursuit and peak velocity during pro-saccades were both worse in ALS patients versus healthy subjects (mean (SD)=0.34(0.06) vs. 0.3(0.07), p = 0.01, and 0.41(0.05) vs. 0.38(0.07), p = 0.04, respectively). Patients with bulbar symptoms (N = 14) had a decreased pro-saccade gain compared with patients without bulbar symptoms (mean (SD)=0.1 (0.04) vs. 0.93 (0.07), p = 0.01), and a larger error rate of anti-saccade movement (mean (SD)=0.42 (0.21) vs. 0.28 (0.16), p = 0.04). Conclusions: Oculometric measures correlated with the clinical assessment and were different from data of healthy subjects. Further studies are warranted to establish the role of oculometrics in the evaluation of patients with ALS and other neurodegenerative disorders, and its possible use in clinical trials.